Capital Fund Management S.A. Increases Stock Holdings in Amicus Therapeutics, Inc. $FOLD

Key Points

• Capital Fund Management S.A. increased its holdings in Amicus Therapeutics by 408.8% during the first quarter, now owning over 312,561 shares valued at approximately $2.55 million.
• Multiple large investors have also added to their positions in Amicus, with PNC Financial Services increasing its stake by 211.4% and GAMMA Investing boosting by 1,610.8% in the same quarter.
• Amicus Therapeutics' stock has experienced an average target price of $16.22 according to analysts, with a consensus rating of "Moderate Buy".

Capital Fund Management S.A. grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 408.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 312,561 shares of the biopharmaceutical company's stock after purchasing an additional 251,134 shares during the quarter. Capital Fund Management S.A. owned approximately 0.10% of Amicus Therapeutics worth $2,550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Amicus Therapeutics in the first quarter worth $53,000. Hsbc Holdings PLC increased its position in Amicus Therapeutics by 20.4% during the first quarter. Hsbc Holdings PLC now owns 50,456 shares of the biopharmaceutical company's stock valued at $412,000 after acquiring an additional 8,536 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Amicus Therapeutics by 2.6% in the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company's stock worth $238,277,000 after purchasing an additional 738,623 shares during the last quarter. Algert Global LLC grew its holdings in shares of Amicus Therapeutics by 92.9% in the first quarter. Algert Global LLC now owns 820,026 shares of the biopharmaceutical company's stock worth $6,691,000 after purchasing an additional 394,943 shares during the last quarter. Finally, Aberdeen Group plc grew its holdings in Amicus Therapeutics by 14.9% during the 1st quarter. Aberdeen Group plc now owns 1,586,609 shares of the biopharmaceutical company's stock worth $12,947,000 after acquiring an additional 205,834 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. UBS Group lifted their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD traded up $0.01 during mid-day trading on Thursday, hitting $7.65. 3,623,470 shares of the company were exchanged, compared to its average volume of 3,857,541. The stock has a 50 day simple moving average of $6.45 and a 200-day simple moving average of $7.15. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of -63.74 and a beta of 0.53. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.